sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×Ó

ǰÑÔ

Ô­·¢ÐԸΰ©(primary liver cancer)ÊÇÌìϹæÄ£ÄÚéæÃüÂÊ×î¸ßµÄ¶ñÐÔÖ×ÁöÖ®Ò»¡£ÎÒ¹úÊǸΰ©·¢²¡ÂʽϸߵĹú¼ÒÖ®Ò» £¬Æä·¢²¡ÂʾÓÎÒ¹ú¶ñÐÔÖ×Áö·¢²¡Âʵĵڶþλ¡£Ô­·¢ÐԸΰ©ÖÐ95£¥ÊôÓÚ¸Îϸ°û¸Î°©(hepatocellular carcinoma,HCC)ÊÇÓÉ»¯Ñ§Ö°©Îï¡¢²¡¶¾µÈ¶àÖÖÒòËØÒýÆðµÄ¸Îϸ°ûÉú³¤Ê§¿Ø¶øµ¼Öµİ©±ä £¬Óë¶àÖÖ»ùÒòµÄµ÷¿ØºÍ±í´ïÇ×½üÏà¹Ø¡£ÏÖÔÚ £¬¸Î°©µÄÖ²¡»úÖÆÉÐδÑо¿ÇåÎú £¬Ëæ×ŶԸΰ©¶¯ÎïÄ£×ÓÑо¿µÄһֱ̽Ë÷ £¬ÒѾ­½¨ÉèÁË×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔ¡¢ÝªÖ²ÐÔ¼°×ª»ùÒò¶¯Îï¸Î°©Ä£×Ó¡£ÓÉÓÚÕâЩģ×ӽϺõØÄ£ÄâÁËÈËÀà¸Î°© £¬Òò¶ø¿ÉÓÃÓڸΰ©µÄÐÄÀí¡¢Ï¸°ûºÍ·Ö×ӵȷ¢²¡»úÖÆ·½ÃæµÄÑо¿ £¬Ò²¿ÉÓÃÓڸΰ©ÖÎÁÆÒ©ÎïµÄɸѡÒÔ¼°»ùÒòÖÎÁƵÄ̽Ë÷¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×ÓÊÇÖ¸Óû¯Ñ§¡¢ÎïÀí¼°ÉúÎïÖ°©ÒòËØ×÷ÓÃÓÚʵÑ鶯Îï £¬Ä£Äâ¸ÎËðÉË£­ÏËά»¯£­¶ñÐÔת»¯µÄÖÜÆÚת±ä £¬ÓÕ·¢¶¯ÎïÐγɵĸΰ©¡£ÏÖÔÚÒÔ»¯Ñ§ÓÕ°©¼ÁÓÕ·¢ÎªÖ÷ £¬³£ÓÃÖ¸ΰ©µÄÎïÖÊÓжþÒÒ»ùÑÇÏõ°·(diethylnitrosamine,DEN)¡¢¶Ô¶þ¼×»ù°±»ùżµª±½(dimethylaminoazobenzene,OBA)¡¢2-ÒÒËá°±»ùËá(2-acetylamino fluorine,2-AAF)¡¢Ñǰ±»ùżµª¼×±½(o-aminoazotolueue,OAT)ºÍ»ÆÇúÃ¹ËØ(aflatoxin,AF)¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

DENÓÕµ¼Ä£×Ó£ºµ¥ÓÃʱ¿É¸øÓèSprague Dawley´óÊó»òWistar´óÊó0.25£¥DENË®ÈÜÒº°´10mg/kg¼ÁÁ¿¹àθ £¬Ã¿ÖÜÒ»´Î £¬Í¬Ê±ÌìÌìÒÔ0.025£¥DENË®ÈÜÒº¹©¶¯ÎïÒûÓà £¬Ò»Á¬Î¹Ñø6¸öÔ¡£»ò¸øÓèÒ»´ÎÐÔ¸¹Ç»×¢Éä0.5£¥DENµÄÎÞ¾úË®ÈÜÒº(100mg/kg), 1Öܺó×îÏÈÒ»Á¬¹©Ó¦100mg/LµÄDENÎÞ¾úË®ÈÜÒº×ÔÓÉÒûÓÃÖ±ÖÁ16ÖÜ£»Æä¼äµÚ9~11ÖܸũӦÎÞ¾úË®¡£DENÒà¿ÉÁªÓÃ2-AAF¼´Solt-FarberÓÕ°©·¨£ºÒ»´ÎÐÔ¸øÓè´óÊó¸¹Ç»×¢Éä200mg/kg DENÈÜÒº £¬2ÖܺóÎ¹Ñøº¬0.02£¥2-AAFËÇÁÏ14Ìì £¬µÚ3ÖÜÐд󲿷ָÎÇгý £¬µÚ4Öָܻ´Í¨Ë×ËÇÁÏÎ¹Ñø¡£

DBAÓÕµ¼Ä£×Ó£º¼´Óú¬0.06£¥DABËÇÁÏÎ¹Ñø £¬²¢¿ØÖÆÎ¬ÉúËØB2º¬Á¿(≤1.5~2.0mg/kg) £¬Ò»Á¬Î¹Ñø4~6¸öÔ¡£

2-AAFÓÕµ¼Ä£×Ó£ºº¬ÓÐ0.05£¥2-AAFËÇÁÏÎ¹ÑøSprague Dawley´óÊó £¬Ò»Á¬3~4¸öÔ¡£

OATÓÕµ¼Ä£×Ó£ºÓú¬1£¥OATÈÜÒº(10mg/ml)Í¿ÔÚСÊóµÄÁ½¼çëÎ¼äÆ¤·ôÉÏ £¬¸ôÈÕ1´Î £¬Ã¿´Î2~3µÎ £¬Ò»Á¬7~8ÖÜ¡£

AFÓÕµ¼Ä£×Ó£º´óÊó¸Î°©Ã¿ÔÂËÇÁÏÖк¬0.001~0.015ppmι6¸öÔ¡£»òÓöþ¼×»ùÑÇí¿(DMSO)ÏûÈÚAF £¬°´ÌìÌì400µg/kg¸¹Ç»×¢Éä1´Î £¬Ò»Á¬2Öܺó×èÖ¹×¢Éä £¬Ò»´ÎÐÔÔÙ×¢Éä0.75~1.50mg/kgµÄAF £¬2ÖܺóÐиδ󲿷ÖÇгýÊõ¡£

¡¾Ä£×ÓÌØµã¡¿£º

DENΪ×î³£¼ûµÄ»¯Ñ§ÓÕ°©¼Á £¬ÓÕ·¢´óÊóÖ°©ÂÊΪ80£¥¡£DBA·¨6¸öÔ¼´¿É±¬·¢¸Î°© £¬ÓÕ°©ÂÊΪ60£¥¡£2-AAFÓÕµ¼3Öܼ´¿É·ºÆð°©Ç°²¡±ä £¬¾µÏ¼û¸Îϸ°û³ÊÂÑÔ²ÐÎϸ°ûÔöÉú £¬ÇҾ߾Þϸ²»µÈµÄ°©³²½á½Ú £¬3¡«4¸öÔºóÓÐ80£¥~90£¥¶¯Îﱬ·¢¸ÎÖ×Áö¡£OATͿĨ·¨¸øÒ©ºó8Öܼ´·ºÆð½á½Ú £¬7¸öÔºó¼´ÓÕ·¢Ð¡Êó¸Î°© £¬ÓÕ°©ÂÊΪ50£¥×óÓÒ¡£AFÓÕ·¢´óÊó¸Î°©±¬·¢ÂÊΪ80% £¬µ«²¡³Ì½Ï³¤ £¬Ö×Áö¶àΪÃÖÂþ½á½ÚÐÍ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

ÓÕ·¢ÐÔÄ£×ÓÆð²¡ÒþÄä¡¢ÓÕµ¼ÖÜÆÚ³¤¡£ÓÕµ¼Àú³ÌÖж¯ÎïµÄéæÃüÂÊ½Ï¸ß £¬¸Î°©±¬·¢µÄ²¿Î»¡¢²¡ÔîÊýʵʱ¼äµÈ¸öÌå²î±ðÒ²½Ï´ó¡£ÏÖÔÚ £¬¸ÃÄ£×Ó¶àÓÃÓڸΰ©²¡Òòѧ¡¢ÒÅ´«Ñ§¼°ÉúÎïѧµÈ·½ÃæµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.³Â»ª £¬ÕÔµÂÃ÷. ¸Î°©¶¯ÎïÄ£×Ó£®ÊµÑ鶯Îïѧ¿ÆÓëÖÎÀí £¬2005,22 (4):32-35

2.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉç £¬2000

3.Å覯 £¬ÕÅäø £¬Àî×Ú·¼ £¬µÈ£®¶þÒÒ»ùÑÇÏõ°·ÓÕ·¢´óÊó¸Î°©Àú³ÌÖÐÆ¢Ôà¾ÞÊÉϸ°ûµÄת±ä£®ÖлªÊµÑéÍâ¿ÆÔÓÖ¾ £¬2009, 26 (5):588-591

4.Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol, 2013, 7 (2):206-223

5.Newell P, Villanueva A,Friedman SL, et al. Experimental models of  hepatocellular carcinoma. J Hepatol, 2008, 48(5):858-879

6.Sonoda A, Nitta N, Nitta-Seko A, el al. Time-coursestudies of implanted rabbit VX2 liver tumors to identify the appropriate time for starting hepatic arterial emholization in animal models. Oncology, 2011, 80 (1-2):92-96

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×Ó
ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×Ó

ǰÑÔ

Ô­·¢ÐԸΰ©(primary liver cancer)ÊÇÌìϹæÄ£ÄÚéæÃüÂÊ×î¸ßµÄ¶ñÐÔÖ×ÁöÖ®Ò»¡£ÎÒ¹úÊǸΰ©·¢²¡ÂʽϸߵĹú¼ÒÖ®Ò» £¬Æä·¢²¡ÂʾÓÎÒ¹ú¶ñÐÔÖ×Áö·¢²¡Âʵĵڶþλ¡£Ô­·¢ÐԸΰ©ÖÐ95£¥ÊôÓÚ¸Îϸ°û¸Î°©(hepatocellular carcinoma,HCC)ÊÇÓÉ»¯Ñ§Ö°©Îï¡¢²¡¶¾µÈ¶àÖÖÒòËØÒýÆðµÄ¸Îϸ°ûÉú³¤Ê§¿Ø¶øµ¼Öµİ©±ä £¬Óë¶àÖÖ»ùÒòµÄµ÷¿ØºÍ±í´ïÇ×½üÏà¹Ø¡£ÏÖÔÚ £¬¸Î°©µÄÖ²¡»úÖÆÉÐδÑо¿ÇåÎú £¬Ëæ×ŶԸΰ©¶¯ÎïÄ£×ÓÑо¿µÄһֱ̽Ë÷ £¬ÒѾ­½¨ÉèÁË×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔ¡¢ÝªÖ²ÐÔ¼°×ª»ùÒò¶¯Îï¸Î°©Ä£×Ó¡£ÓÉÓÚÕâЩģ×ӽϺõØÄ£ÄâÁËÈËÀà¸Î°© £¬Òò¶ø¿ÉÓÃÓڸΰ©µÄÐÄÀí¡¢Ï¸°ûºÍ·Ö×ӵȷ¢²¡»úÖÆ·½ÃæµÄÑо¿ £¬Ò²¿ÉÓÃÓڸΰ©ÖÎÁÆÒ©ÎïµÄɸѡÒÔ¼°»ùÒòÖÎÁƵÄ̽Ë÷¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×ÓÊÇÖ¸Óû¯Ñ§¡¢ÎïÀí¼°ÉúÎïÖ°©ÒòËØ×÷ÓÃÓÚʵÑ鶯Îï £¬Ä£Äâ¸ÎËðÉË£­ÏËά»¯£­¶ñÐÔת»¯µÄÖÜÆÚת±ä £¬ÓÕ·¢¶¯ÎïÐγɵĸΰ©¡£ÏÖÔÚÒÔ»¯Ñ§ÓÕ°©¼ÁÓÕ·¢ÎªÖ÷ £¬³£ÓÃÖ¸ΰ©µÄÎïÖÊÓжþÒÒ»ùÑÇÏõ°·(diethylnitrosamine,DEN)¡¢¶Ô¶þ¼×»ù°±»ùżµª±½(dimethylaminoazobenzene,OBA)¡¢2-ÒÒËá°±»ùËá(2-acetylamino fluorine,2-AAF)¡¢Ñǰ±»ùżµª¼×±½(o-aminoazotolueue,OAT)ºÍ»ÆÇúÃ¹ËØ(aflatoxin,AF)¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

DENÓÕµ¼Ä£×Ó£ºµ¥ÓÃʱ¿É¸øÓèSprague Dawley´óÊó»òWistar´óÊó0.25£¥DENË®ÈÜÒº°´10mg/kg¼ÁÁ¿¹àθ £¬Ã¿ÖÜÒ»´Î £¬Í¬Ê±ÌìÌìÒÔ0.025£¥DENË®ÈÜÒº¹©¶¯ÎïÒûÓà £¬Ò»Á¬Î¹Ñø6¸öÔ¡£»ò¸øÓèÒ»´ÎÐÔ¸¹Ç»×¢Éä0.5£¥DENµÄÎÞ¾úË®ÈÜÒº(100mg/kg), 1Öܺó×îÏÈÒ»Á¬¹©Ó¦100mg/LµÄDENÎÞ¾úË®ÈÜÒº×ÔÓÉÒûÓÃÖ±ÖÁ16ÖÜ£»Æä¼äµÚ9~11ÖܸũӦÎÞ¾úË®¡£DENÒà¿ÉÁªÓÃ2-AAF¼´Solt-FarberÓÕ°©·¨£ºÒ»´ÎÐÔ¸øÓè´óÊó¸¹Ç»×¢Éä200mg/kg DENÈÜÒº £¬2ÖܺóÎ¹Ñøº¬0.02£¥2-AAFËÇÁÏ14Ìì £¬µÚ3ÖÜÐд󲿷ָÎÇгý £¬µÚ4Öָܻ´Í¨Ë×ËÇÁÏÎ¹Ñø¡£

DBAÓÕµ¼Ä£×Ó£º¼´Óú¬0.06£¥DABËÇÁÏÎ¹Ñø £¬²¢¿ØÖÆÎ¬ÉúËØB2º¬Á¿(≤1.5~2.0mg/kg) £¬Ò»Á¬Î¹Ñø4~6¸öÔ¡£

2-AAFÓÕµ¼Ä£×Ó£ºº¬ÓÐ0.05£¥2-AAFËÇÁÏÎ¹ÑøSprague Dawley´óÊó £¬Ò»Á¬3~4¸öÔ¡£

OATÓÕµ¼Ä£×Ó£ºÓú¬1£¥OATÈÜÒº(10mg/ml)Í¿ÔÚСÊóµÄÁ½¼çëÎ¼äÆ¤·ôÉÏ £¬¸ôÈÕ1´Î £¬Ã¿´Î2~3µÎ £¬Ò»Á¬7~8ÖÜ¡£

AFÓÕµ¼Ä£×Ó£º´óÊó¸Î°©Ã¿ÔÂËÇÁÏÖк¬0.001~0.015ppmι6¸öÔ¡£»òÓöþ¼×»ùÑÇí¿(DMSO)ÏûÈÚAF £¬°´ÌìÌì400µg/kg¸¹Ç»×¢Éä1´Î £¬Ò»Á¬2Öܺó×èÖ¹×¢Éä £¬Ò»´ÎÐÔÔÙ×¢Éä0.75~1.50mg/kgµÄAF £¬2ÖܺóÐиδ󲿷ÖÇгýÊõ¡£

¡¾Ä£×ÓÌØµã¡¿£º

DENΪ×î³£¼ûµÄ»¯Ñ§ÓÕ°©¼Á £¬ÓÕ·¢´óÊóÖ°©ÂÊΪ80£¥¡£DBA·¨6¸öÔ¼´¿É±¬·¢¸Î°© £¬ÓÕ°©ÂÊΪ60£¥¡£2-AAFÓÕµ¼3Öܼ´¿É·ºÆð°©Ç°²¡±ä £¬¾µÏ¼û¸Îϸ°û³ÊÂÑÔ²ÐÎϸ°ûÔöÉú £¬ÇҾ߾Þϸ²»µÈµÄ°©³²½á½Ú £¬3¡«4¸öÔºóÓÐ80£¥~90£¥¶¯Îﱬ·¢¸ÎÖ×Áö¡£OATͿĨ·¨¸øÒ©ºó8Öܼ´·ºÆð½á½Ú £¬7¸öÔºó¼´ÓÕ·¢Ð¡Êó¸Î°© £¬ÓÕ°©ÂÊΪ50£¥×óÓÒ¡£AFÓÕ·¢´óÊó¸Î°©±¬·¢ÂÊΪ80% £¬µ«²¡³Ì½Ï³¤ £¬Ö×Áö¶àΪÃÖÂþ½á½ÚÐÍ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

ÓÕ·¢ÐÔÄ£×ÓÆð²¡ÒþÄä¡¢ÓÕµ¼ÖÜÆÚ³¤¡£ÓÕµ¼Àú³ÌÖж¯ÎïµÄéæÃüÂÊ½Ï¸ß £¬¸Î°©±¬·¢µÄ²¿Î»¡¢²¡ÔîÊýʵʱ¼äµÈ¸öÌå²î±ðÒ²½Ï´ó¡£ÏÖÔÚ £¬¸ÃÄ£×Ó¶àÓÃÓڸΰ©²¡Òòѧ¡¢ÒÅ´«Ñ§¼°ÉúÎïѧµÈ·½ÃæµÄÑо¿¡£

 

²Î¿¼ÎÄÏ×£º

1.³Â»ª £¬ÕÔµÂÃ÷. ¸Î°©¶¯ÎïÄ£×Ó£®ÊµÑ鶯Îïѧ¿ÆÓëÖÎÀí £¬2005,22 (4):32-35

2.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉç £¬2000

3.Å覯 £¬ÕÅäø £¬Àî×Ú·¼ £¬µÈ£®¶þÒÒ»ùÑÇÏõ°·ÓÕ·¢´óÊó¸Î°©Àú³ÌÖÐÆ¢Ôà¾ÞÊÉϸ°ûµÄת±ä£®ÖлªÊµÑéÍâ¿ÆÔÓÖ¾ £¬2009, 26 (5):588-591

4.Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol, 2013, 7 (2):206-223

5.Newell P, Villanueva A,Friedman SL, et al. Experimental models of  hepatocellular carcinoma. J Hepatol, 2008, 48(5):858-879

6.Sonoda A, Nitta N, Nitta-Seko A, el al. Time-coursestudies of implanted rabbit VX2 liver tumors to identify the appropriate time for starting hepatic arterial emholization in animal models. Oncology, 2011, 80 (1-2):92-96

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿